Clinical Trial Update: A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the effect of rifampin on navitoclax metabolism; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Lymphoma
• Solid Tumors

Drugs mentioned

• Navitoclax (navitoclax)
• RIFAMPIN (RIFAMPIN)

Snippet

Sponsor: AbbVie | Conditions: Lymphoma, Including Chronic Lymphocytic Leukemia, Solid Tumors | Phase 1 | Status: COMPLETED